l Inombolo yeCas: 171596-29-5 Ifomula yeMolekyuli: C₂₂H₁₉N₃O₄
| Indawo yokunyibilika | >193°C |
| Ukuxinana | I-DMF: 25 mg / ml I-DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml I-DMSO: 20 mg / ml |
| ixesha lokugcina | -20°C |
| ukunyibilika | I-DMF: 25 mg / ml I-DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml I-DMSO: 20 mg / ml |
| umsebenzi wamehlo | [α]/D +68 ukuya +78°, c = 1 kwi-chloroform-d |
| Imbonakalo | Mhlophe ukuya kuMhlophe Okuqinileyo |
| Ubunyulu | ≥98% |
(igama lemarike okanye ) luhlobo lwe-PDE5 inhibitor esetyenziselwa unyango lwe-erectile dysfunction, i-benign prostatic hypertrophy kunye ne-pulmonary arterial hypertension.Umphumo wokuphumza imithambo yegazi kunye nokwandisa ukuhamba kwegazi kwi-corpus cavernosum.Indlela yokusebenza ngokuthintela umsebenzi we-cGMP uhlobo oluthile lwe-phosphodiesterase 5 (PDE5).I-PDE5 ithoba i-cGMP kwi-corpus cavernosum ejikeleze ipipi.Ke ngoko, i-tadalafi ikhokelela ekunyukeni koxinzelelo lwe-cGMP ebangela ngakumbi ukuphumla kwemisipha kunye nokwanda kokuhamba kwegazi kwi-corpus cavernosum.Olunye uphononongo lweklinikhi lukwabonisa ukuba kunokuphucula ukusebenza kwe-endothelia kumadoda anomngcipheko owonyukileyo wentliziyo kunye nokwehlisa iimpawu zendlela yomchamo kwi-benign prostatic hyperplasia.
i-analgesic, i-blocker yokuthatha, i-agonist ye-mu-opiod receptor.I-phosphodiesterase 5 inhibitor.isetyenziselwa unyango lwe-erectile dysfunction.
ihluke kwisakhiwo esivela kwi-sildenafil kunye ne-vardenafil.Ifakwe ngokukhawuleza kwaye iphakame ekugxininiseni (378 μg / L emva kwe-dose ye-20-mg) emva kweeyure ze-2, ibonisa isiqingatha sobomi beeyure ze-17.5.Kwakhona i-metabolized yisibindi (CYP3A4).Ngokucacileyo, i-pharmacokinetics yayo ayichaphazeli ngokwezonyango kutywala okanye ukutya okanye izinto ezifana nesifo seswekile okanye ukungasebenzi kakuhle kwesibindi okanye izintso.
